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Abstract
Cancer is the third leading cause of death in Kenya. However, there is scarce information on the nutritional status of cancer patients to guide in decision
making. The present study sought to assess the risk of malnutrition, and factors associated with malnutrition and cachexia, among cancer out-patients, with
the aim of informing nutrition programmes for cancer management in Kenya and beyond. This was a facility-based cross-sectional study performed at
Kenyatta National Hospital and Texas Cancer Centre in Nairobi, Kenya. The risk of malnutrition was assessed using the Malnutrition Universal
Screening Tool (MUST). Diagnoses of malnutrition and cachexia were done using the European Society of Clinical Nutrition and Metabolism
(ESPEN) and Fearon criteria, respectively. A total of 512 participants were assessed. Those at risk of malnutrition were 33·1 % (12·5 % at medium
risk, 20·6 % at high risk). Prevalence of malnutrition was 13·4 %. The overall weight loss >5 % over 3 months was 18·2 % and low fat-free mass
index was 43·1 %. Prevalence of cachexia was 14·1 % compared with 8·5 % obtained using the local criteria. Only 18·6 % participants had received
any form of nutrition services. Age was a predictor of malnutrition and cachexia in addition to site of cancer for malnutrition and cigarette smoking
for cachexia. The use of the MUST as a screening tool at the ﬁrst point of care should be explored. The predictive value of current nutrition assessment
tools, and the local diagnostic criteria for malnutrition and cachexia should be reassessed to inform the development of appropriate clinical guidelines and
future capacity-building initiatives that will ensure the correct identiﬁcation of patients at risk for timely care.
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Cancer is the third leading cause of death in Kenya with a
mortality rate estimated at 26 941 annually(1). Malnutrition
and cachexia are common in cancer and often contribute to
poor health outcomes. Malnutrition is a clinical condition
characterised by an imbalance of energy, protein and other
nutrients that causes measurable adverse effects on body tis-
sue, function and clinical outcome(2). Cancer cachexia is a
multifactorial syndrome characterised by an ongoing loss of
skeletal muscle mass, with or without loss of fat mass that can-
not be fully reversed by conventional nutrition support(3).
Cachexia is a manifestation in advanced cancer that affects
50–80 % of cancer patients and accounts for up to 20 % of
cancer deaths(4,5). Early detection and management of malnu-
trition and cachexia are therefore key. This has necessitated the
integration of nutrition care in cancer management for
improved clinical outcomes and quality of life(6).
Abbreviations: AOR, adjusted OR; ESPEN, European Society of Clinical Nutrition and Metabolism; FFMI, fat-free mass index; FVS, Food Variety Score; KEMRI, Kenya
Medical Research Institute; KNH, Kenyatta National Hospital; MUST, Malnutrition Universal Screening Tool; TCC, Texas Cancer Centre.
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The 2013 National Guidelines for Cancer Management in
Kenya identiﬁes nutrition care for persons with cancer as an
integral part of cancer treatment(7). It singles out the need
for early initiation of management plans that incorporate nutri-
tional assessment, diagnosis and intervention. BMI and weight
loss are currently the main indicators of malnutrition and cach-
exia, respectively, in Kenyan public hospitals. However, previ-
ous studies have shown the limitations of using BMI as the
sole indicator of malnutrition in cancer because it can yield
high or normal results in patients with large tumours, ascites
or oedema, thereby masking weight loss. Unintentional weight
loss is instead recommended(8,9).
The Malnutrition Universal Screening Tool (MUST) is
designed to identify adults who are underweight or obese
and at risk of malnutrition, and who may beneﬁt from appro-
priate intervention(2). It uses BMI, weight loss and acute
disease effect scores in estimating the overall risk of malnutri-
tion. The European Society of Clinical Nutrition and
Metabolism (ESPEN) consensus statement provides a min-
imum set of criteria for the diagnosis of malnutrition that
can be applied independently of clinical setting and aeti-
ology(10). It allows for inclusion of parameters such as fat-free
mass where applicable in diagnosing malnutrition. The inter-
national consensus on deﬁnition and classiﬁcation of cancer
cachexia also provides diagnostic criteria for cachexia that
include weight loss or loss of skeletal muscle mass(3). These
assessments enrich understanding of the variability in nutri-
tional status, and have the potential to alter cancer treatment
paradigms for improved health outcomes(11,12).
There is scarce information on the burden of malnutrition
and cachexia among cancer out-patients in Kenya to inform
decision making and policy(1). In view of the lack of informa-
tion and the recent advances in screening and diagnosis of
malnutrition and cachexia, this study sought to establish the
risk of malnutrition, and factors associated with the occurrence
of malnutrition and cachexia, with the ultimate aim of inform-
ing nutrition programmes for cancer management in Kenya
and beyond.
Research methods
Study design and population
This was a facility-based cross-sectional study among cancer
out-patients seeking treatment at Kenyatta National Hospital
(KNH) and Texas Cancer Centre (TCC) in Nairobi, Kenya.
KNH is the largest public referral hospital in Kenya. The
KNH cancer treatment centre receives more than 22 000 can-
cer patients annually(13). TCC, on the other hand, is a private
facility that receives approximately 1092 cancer patients
annually(14).
Inclusion criteria
The study included all out-patients with conﬁrmed stage I–IV
cancer disease, aged above 18 years and receiving treatment
(radiotherapy, chemotherapy, surgery or hormonal) in the
two selected cancer treatment sites.
Sample size estimation and allocation
Prevalence of malnutrition among cancer patients in Kenya
remains unknown. Using the Fischer formula(15), a sample
size of 512 participants was calculated factoring in a 10 % non-
response rate. The calculated sample size was distributed
between the two facilities using the square root allocation
method to ensure appropriate representation of the two facilities
based on the number of patients received per facility per year. A
systematic random sampling method was used in recruiting par-
ticipants until the desired sample size was achieved. This
entailed obtaining the total number of patients expected in
each facility from the hospital records and selecting a random
starting point. The sampling interval was determined by divid-
ing the total number expected by the desired sample size.
Recruitment and training of research assistants
Research assistants with a medical background were recruited
and trained on the protocol, study procedures including the
consenting process, study tools and on proper data collection
using pretested data collection tools. Training and certiﬁcation
were done to harmonise data collection methods between
researchers. This was followed by piloting of the study tools
and deﬁnitive data collection.
Assessments
Sociodemographic assessments. Data collection was done
between June and July 2016. Interviews were carried out and
information on socio-economic and demographic characteristics
collected using a pretested structured questionnaire.
Education level was categorised into four categories: none,
primary (1–8 years), secondary (9–14 years), and tertiary (>14
years). Occupation was classiﬁed as formal, non-formal,
unemployed and retirees.
Anthropometric assessments. Weight and height were
measured using calibrated Seca 762 classic mechanical
medical weighing scales and UNICEF standard height
boards, and ﬁndings recorded to the nearest 0·1 kg and 0·1
cm, respectively. In measuring height, participants were
asked to stand upright, without head gear and shoes, arms
hanging loosely at the sides, feet slightly apart, and with the
back of the heels and head against the stadiometer. In
measuring weight, the scale was placed on a ﬂat surface and
zero checked before every measurement. Participants were
weighed without shoes while wearing minimal clothing.
Weight and height measurements were used to compute
BMI using the formula of BMI = weight (kg)/height (m2).
Information on weight history was retrieved from patients’
medical records and used to calculate changes in weight.
The current weight was deducted from the previous weight
to calculate the amount of weight lost.
Body composition assessments. Total body fat, body water
and lean mass percentages were estimated using a
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commercially available single-frequency four-electrode
bioimpedance analyser system (Bodystat 1500). Tetrapolar
hand to foot measurements were performed in a supine
position lasting for 15 min. The gel-ﬁlled electrodes were
placed on the dorsal surfaces of the right hand and foot,
distal ones being, respectively, proximal to the metacarpal
and metatarsal phalangeal joints in accordance with standard
tetrapolar electrode placement to minimise gap
impedence(16). The instrument recorded whole body
impedance from the hands to the feet by applying an electric
alternating current ﬂux of 0·8 A at an operating frequency of
50 kHz. Fat-free mass index (FFMI) was calculated using
the formula FFMI = lean body mass (kg)/height (m2).
Clinical and dietary assessments. Details on participants’
diagnosis (clinical history, types of cancer and clinical stages)
and treatment were retrieved from patient ﬁles. Information
on symptoms such as lack of appetite, feeling nauseated or
vomiting was self-reported. Dietary diversity was assessed
using individual Food Variety Scores (FVS) that collect data
on speciﬁc food items consumed(17). Participants provided
details on the variety of foods consumed 7 d and 24 h prior
to the interview. Each food item was given a score of 1 if
consumed at least once over 24 h and the 7 d period
regardless of the frequency. The FVS were classiﬁed as
either adequate by creating a cut-off point where the mean
of the upper tercile was used to classify the respondent as
either having adequate or inadequate dietary diversity.
Risk of malnutrition. Participants were screened using the
MUST to identify those at risk of malnutrition. The overall
risk was an aggregate of BMI, weight loss and acute disease
scores whose cut-off points and interpretation of the data
were done in accordance with MUST guidelines(2). BMI
cut-offs of >20, 18·5–20 and <18·5 kg/m2 were scored as
0, 1 and 2, respectively. Unplanned weight loss of <5, 5–10
and >10 % in the past 3–6 months was scored as 0, 1 and
2, respectively. The acute disease effect did not apply to the
out-patients and was scored a zero. A score aggregate of 0,
1 and 2 represented low, medium and high risk of
malnutrition, respectively.
Diagnosis of malnutrition. Diagnosis of malnutrition was
done in accordance with the ESPEN criteria for the
diagnosis of malnutrition(10). The criteria provide for the use
of low BMI (<18·5 kg/m2), or combined ﬁnding of
unintentional weight loss of >5 % over 3 months and at
least one of either a reduced BMI of <20 kg/m2 or <22 kg/
m2 in subjects younger and older than 70 years, respectively,
or a low FFMI of <15 kg/m2 and <17 kg/m2 in females
and males, respectively, to diagnose malnutrition. Similar to
ESPEN, the local criterion uses low BMI in diagnosing
malnutrition; hence further bivariate and multivariate
analyses were done using low BMI.
Diagnosis of cachexia. Diagnosis of cachexia was in
accordance with the Fearon criteria for the assessment of
cachexia(3). Diagnosis of cancer cachexia was based on BMI
< 20 kg/m2 and any degree of weight loss >2 %. The local
deﬁnition of cachexia is >5 % weight loss/month or >10 %
weight loss over 6 months(7).
Information from the MUST will be used to identify
patients at risk of malnutrition for targeted intervention. In
addition to information on malnutrition based on low BMI,
differences in malnutrition based on weight loss and either a
reduced age-speciﬁc BMI or low sex-speciﬁc FFMI diagnostic
criteria will help inform clinical practice, the development of
guidelines and appropriate care plans for cancer out-patients
in Kenya.
Ethical considerations. This study was conducted according
to the guidelines laid down in the Declaration of Helsinki
and all procedures involving human subjects were approved
by the Kenya Medical Research Institute (KEMRI) Scientiﬁc
and Ethics Review Unit (reference: KEMRI/SERU/CPHR/
001/3026) and the KNH Ethics and Research Review
Committee (registration certiﬁcate: P462/07/2015). Written
informed consent was obtained from all study subjects.
Data management and statistical analysis. Quantitative data
were double-entered using the Microsoft Access application.
Clean and validated data were exported to SPSS version 20.0
statistical software (IBM Corp.) for data analysis.
Exploratory data analysis techniques were used at the initial
stage of analysis to uncover the data distribution
characteristics of continuous variables and identify outliers.
Descriptive statistics such as proportions and frequency
distributions were used to summarise categorical variables
and measures of central tendency and dispersion for
continuous variables. Pearson’s χ2 test or Fisher’s exact test,
where applicable, was used to assess the relationship
between dependent and independent categorical variables.
To test for association between independent continuous
variables and dependent categorical variables, the unpaired
Student’s t test for normally distributed continuous variables
and the Mann–Whitney U test for non-normally distributed
continuous variables were used for dichotomous dependent
categorical variable. For dependent categorical variables with
more than two categories, one-way ANOVA for normally
distributed continuous variables and Kruskal–Wallis one-way
ANOVA for non-normally distributed continuous variables
were carried out. The threshold for statistical signiﬁcance
was set at α = 0·05 (two-sided). Post hoc grouping of study
participants was done during analysis since this was a
comparative study.
Results
A total of 512 participants were recruited (male: 28·1 %;
female: 71·9 %). The mean age was 52 (SD 13·8) years. The
majority of the participants (71·7 %) were aged 40 years and
above, 20·3 % were in formal employment, and 9·8 % had
3
journals.cambridge.org/jns
D
ow
nl
oa
de
d 
fr
om
 h
tt
ps
:/
/w
w
w
.c
am
br
id
ge
.o
rg
/c
or
e.
 R
on
go
 U
ni
ve
rs
ity
 C
ol
le
ge
, o
n 
19
 F
eb
 2
01
8 
at
 0
6:
39
:0
0,
 s
ub
je
ct
 to
 th
e 
C
am
br
id
ge
 C
or
e 
te
rm
s 
of
 u
se
, a
va
ila
bl
e 
at
 h
tt
ps
:/
/w
w
w
.c
am
br
id
ge
.o
rg
/c
or
e/
te
rm
s.
 h
tt
ps
:/
/d
oi
.o
rg
/1
0.
10
17
/j
ns
.2
01
7.
61
not received formal education. The top three site cancers were
cancer of the breast (28·7 %), female genital (22·7 %) and
digestive organs (21·7 %). The majority (260; 52 %) of the
patients presented with late-stage cancer (stages III and IV)
compared with 213 (42·6 %) with early-stage cancer (stages
0, I and II). Table 1 shows the sociodemographic and clinical
characteristics of the study participants.
Breast (39·7 %) and cervical (25 %) cancer were the leading
cancers in females, and prostate (24 %) and oesophagus (24
%) in males. Up to 470 (91·8 %) participants were on treat-
ment, out of whom 202 (43 %) were on one form of treatment
(chemotherapy 114 (24·3 %), surgery sixteen (3·4 %), radio-
therapy sixty-eight (14·5 %) and hormonal therapy four (0·8
%)), while 183 (38·9 %) and eighty-ﬁve (18·1 %) were on
two and three combined forms of treatments, respectively.
Fatigue and poor appetite were reportedly the most common
symptoms experienced in the previous 24 h (38·3 and 32·4 %),
and 1 month at 50 and 51 %, respectively. Up to 35 %
reported feeling nauseated while 28 % had vomited in the pre-
vious 1 month. Only 18·6 % of the participants reported hav-
ing received nutrition services in the form of nutrition
counselling and education or food support during their hos-
pital visits.
Risk of malnutrition
The risk of malnutrition was assessed in 471 participants.
Those found at risk of malnutrition were 33·1 % (12·5 % at
medium risk and 20·6 % at high risk). The risk of malnutrition
was signiﬁcantly higher in males (OR 2·84 (95 % CI 1·87,
4·31); P < 0·001), patients who smoked cigarettes (OR 2·86
(95 % CI 1·76, 4·66); P < 0·001), those with stage II cancer
disease (OR 1·97 (95 % CI 1·12, 3·43); P= 0·017), and
those on radiotherapy treatment (OR 2·35 (95 % CI 1·36,
4·06); P = 0·002), as shown in Table 2. Those aged <30
years were less likely to be at risk (OR 0·26 (95 % CI 0·09,
0·67); P < 0·001), and so were patients with breast cancer
(OR 0·34 (95 % CI 0·18, 0·63); P= 0·001).
Prevalence and factors associated with malnutrition
Malnutrition was assessed in 506 participants. Malnutrition
based on BMI < 18·5 kg/m2 was 13·4 % (males, 24·8 %;
females, 8·9 %). Bivariate analysis revealed males to be 3·39
(95 % CI 2·01, 5·73) times likely to be malnourished com-
pared with females. Likewise, the odds of having malnutrition
were higher among cigarette smokers (3·19 (95 % CI 1·81,
5·60); P < 0·001), alcohol consumers (2·01 (95 % CI 1·20,
3·38), P = 0·008), patients with stage II cancer (2·30 (95 %
CI 1·02, 5·17); P= 0·044), those with cancer in digestive
organs (2·56 (95 % CI 1·22, 5·35); P = 0·012), and those
undergoing surgery (3·26 (95 % CI 1·35, 7·86); P = 0·002)
and radiotherapy treatment (2·37 (95 % CI 1·19, 4·69); P =
0·002). The opposite was observed in patients less than 30
years of age and those with breast cancer disease, as shown
in Table 3.
The overall weight loss >5 % over 3 months was 18·2 %
and low FFMI 43·1 %. Malnutrition based on the combined
ﬁndings of unintentional weight loss of >5 % over 3 months
together with age-speciﬁc reduced BMI was 8·6 %, and with
sex-speciﬁc low FFMI was 11·5 %.
The mean FVS was 14·4 (SD 5·6). BMI was signiﬁcantly
associated with the previous 24 h and 7 d FVS at P < 0·001
and P < 0·003, respectively. A majority (97 %) of participants
with low BMI reported inadequate dietary diversity.
Prevalence and factors associated with cachexia
The prevalence of cachexia based on the Fearon criteria was
14·1 %. Being male, cigarette smoking, alcohol consumption
and radiotherapy treatment were signiﬁcantly associated with
cachexia, as shown in Table 4. Males were 3·99 (95 % CI
2·39–6·67; P < 0·001) times more likely to have cachexia com-
pared with females. The odds were higher among cigarette
smokers (OR 3·95 (95 % CI 2·29, 6·82); P< 0·001), alcohol
Table 1. Sociodemographic and clinical characteristics of study
participants (n 512)
(Numbers and percentages)
Characteristics n %
Sex
Female 368 71·9
Male 144 28·1
Age (years)
Mean 52·01
SD 13·78
<30 years 22 4·3
30–39 years 72 14·1
40–49 years 133 26·0
50–59 years 135 26·4
60 years and above 150 29·3
Education levels
No formal education 50 9·8
Primary 195 38·1
Secondary 171 33·4
Tertiary 96 18·8
Occupation
Formal 104 20·3
Non-formal 198 38·7
Unemployed 170 33·2
Retired 40 7·8
Marital
Married 378 73·8
Single 75 14·6
Other* 59 11·5
Stage of cancer (n 500)
Stage 0 4 0·8
Stage 1 75 15·0
Stage 2 134 26·8
Stage 3 141 28·2
Stage 4 119 23·8
Unknown 27 5·4
Site of cancer
Breast (C50) 147 28·7
Female genital (C51–58) 116 22·7
Digestive organs (C15–26) 111 21·7
Lip, oral cavity and pharynx (C00–14) 94 18·4
Haematopoietic (C81–96) 9 1·8
Bone, cartilage, melanoma (C40–43) 18 3·5
Respiratory organs (C30–39) 9 1·8
Kaposi sarcoma (C46) 8 1·6
* Divorced, widowed or separated.
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consumers (OR 1·91 (95 % CI 1·15, 3·17); P = 0·012) and
patients on radiotherapy treatment (OR 2·63 (95 % CI 1·39,
4·97); P= 0·003). Patients with breast cancer were 0·19 (95 %
CI 0·07, 0·51, P = 0·001) times more likely to have cachexia
compared with those with lip, oral cavity and pharynx cancer.
Unlike malnutrition, patients <30 years of age were 6·52 (95 %
CI 2·45, 17·36; P < 0·001) times more likely to have cachexia.
Prevalence of cachexia based on the local deﬁnition of cach-
exia (>10 % weight loss over 6 months) was 8·5 %.
Predictors of risk of malnutrition, malnutrition and cachexia
Binary logistic regression using the backward conditional
method was performed to examine the effect of independent
predictors on the risk of malnutrition, malnutrition and cach-
exia. Age, cigarette smoking and site of cancer were considered
for multivariate analysis. The risk of malnutrition was signiﬁ-
cantly associated with age <30 years (adjusted OR (AOR)
0·21 (95 % CI 0·07, 0·62); P = 0·005), the 30–39 years age
group (AOR 0·41 (95 % CI 0·20, 0·84); P = 0·015), cigarette
smoking (AOR 0·36 (95 % CI 0·20, 0·67); P = 0·001) and
bone, cartilage and melanoma cancer (AOR 2·95 (95 % CI
1·42, 6·12); P = 0·004). Malnutrition was signiﬁcantly asso-
ciated with age <30 years (AOR 0·12 (95 % CI 0·03, 0·413);
P= 0·001), cigarette smoking (AOR 0·31 (95 % CI 0·15,
0·65); P = 0·002), digestive organ cancer (AOR 6·79 (95 %
CI 1·38, 33·34); P = 0·018) and breast cancer (AOR 0·30
(95 % CI 0·13, 0·70); P = 0·005). Cachexia was signiﬁcantly
associated with age <30 years (AOR 10·71 (95 % CI 3·16,
36·32); P < 0·001) and cigarette smoking (AOR 2·72 (95 %
CI 1·23, 6·02); P = 0·014). Table 5 shows age, cigarette smok-
ing and site of cancer as predictors of risk and presence of
malnutrition, and only age and cigarette smoking for cachexia.
Discussion
The present study sought to establish the prevalence and fac-
tors associated with malnutrition and cachexia among cancer
Table 2. Sociodemographic and clinical factors associated with risk of malnutrition
(Numbers and percentages; odds ratios and 95 % confidence intervals)
At risk* Not at risk*
Characteristic n % n % OR 95 % CI P
Overall 156 33·1 315 66·9
Sex
Female 89 57·1 249 79·0 Reference
Male 67 42·9 66 21·0 2·84 1·87, 4·31 <0·001
Age
<30 years 13 8·3 8 2·5 0·26 0·09, 0·67 0·006
30–39 years 25 16·0 44 14·0 0·74 0·39, 1·37 0·335
40–49 years 35 22·4 88 27·9 1·05 0·61, 1·81 0·848
50–59 years 44 28·2 82 26·0 0·78 0·46, 1·31 0·356
60 years and above 39 25·0 93 29·5 Reference
Cigarette smoking
Yes 44 28·2 38 12·1 2·86 1·76, 4·66 <0·001
No 112 71·8 277 87·9 Reference
Alcohol consumption
Yes 61 39·1 95 30·2 1·49 1·00, 2·22 0·053
No 95 60·9 220 69·8 Reference
Stage of cancer
Unknown 12 7·9 13 4·2 0·71 0·29, 1·70 0·444
Stage 0 0 0 3 1·0 UD UD
Stage 1 26 17·2 43 13·9 1·08 0·58, 2·01 0·793
Stage 2 31 20·5 93 30·1 1·97 1·12, 3·43 0·017
Stage 3 38 25·2 90 29·1 1·56 0·91, 2·66 0·107
Stage 4 44 29·1 67 21·7 Reference
Site of cancer
Lip, oral cavity and pharynx (C00–14) 33 21·2 54 17·1 Reference
Digestive organs (C15–26) 46 29·5 53 16·8 1·42 0·79, 2·55 0·241
Respiratory organs (C30–39) 3 1·9 4 1·3 1·22 0·25, 5·83 0·797
Bone, cartilage, melanoma (C40–43) 9 5·8 7 2·2 2·10 0·72, 6·18 0·176
Breast (C50) 24 15·4 116 36·8 0·34 0·18, 0·63 0·001
Female genital (C51–58) 35 22·4 73 23·2 0·78 0·43, 1·42 0·421
Haematopoietic (C81–96) 5 3·2 3 1·0 2·72 0·61, 12·17 0·189
Kaposi sarcoma (C46) 1 0·6 5 1·6 0·32 0·03, 2·93 0·318
Type of treatment
Chemotherapy 95 68·8 238 82·1 Reference
Surgery 10 7·2 17 5·9 1·47 0·65, 3·33 0·352
Radiotherapy 31 22·5 33 11·4 2·35 1·36, 4·06 0·002
Hormonal therapy 1 0·3 2 1·4 5·01 0·45, 55·91 0·19
UD, undetermined; MUST, Malnutrition Universal Screening Tool.
* Risk of malnutrition assessed using the MUST ((BMI cut-offs of >20, 18·5–20 and <18·5 kg/m2 representing low, medium and high risk, respectively) + (unplanned weight loss of
<5 %, 5–10 % and >10 % in the past 3–6 months representing low, medium and high risk, respectively)).
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out-patients in Nairobi, Kenya. A third of the patients were
found to be at risk of malnutrition, while 13·4 and 14·1 %
had malnutrition and cachexia, respectively. Our ﬁndings con-
ﬁrm previous results that show malnutrition and cachexia as
common nutritional challenges among cancer patients, and
that negatively make an impact on the response to cancer treat-
ment, quality of life and overall prognosis(18–21). Malnutrition
and cachexia are poor prognostic factors and should be pre-
vented or detected and managed early enough(18,22). Those
found at risk of malnutrition should therefore be closely mon-
itored to avert progression to frank malnutrition. Mechanisms
should also be put in place to identify patients at risk of cach-
exia for the initiation of preventive interventions(3).
The leading cancers were breast and cervical cancer in
females and prostate and oesophageal cancer in males. Our
ﬁndings agree with the Global Burden of Disease 2016 report
that showed prostate and breast cancer as the leading types of
cancer in men and women, respectively(23). Up to 24 % of
males and close to 10 % of females presented with
oesophageal cancer that has been found to contribute to
some of the highest incidences of malnutrition(21). This
might partly explain the signiﬁcant association observed
between malnutrition and cancer of digestive organs in the
present study.
Up to 28·2 % presented with stage III cancer disease.
However, the odds of being at risk and having malnutrition
were higher among patients with stage II cancer disease.
Previous studies have shown that many cancer patients in
Africa are diagnosed with advanced cancer and easily become
malnourished(24,25). In light of the present ﬁndings on
increased odds of malnutrition in early cancer and the fact
that 81 % of the patients do not receive nutrition services,
there is need for enhanced early screening that can be achieved
by integrating nutrition services across the four levels of health
care in Kenya.
Many factors can modify nutritional status in cancer patients
including nausea, vomiting, decreased energy intake or oncolo-
gic treatments resulting in malnutrition(26,27). More than 50 %
Table 3. Sociodemographic and clinical factors associated with malnutrition
(Numbers and percentages; odds ratios and 95 % confidence intervals)
With malnutrition*
Without
malnutrition*
Characteristic n % n % OR 95 % CI P
Overall 68 13·4 438 86·6
Sex
Female 32 47·1 329 75·1 Reference
Male 36 52·9 109 24·9 3·39 2·01, 5·73 <0·001
Age
<30 years 8 11·8 14 3·2 0·23 0·08, 0·63 0·004
30–39 years 9 13·2 62 14·2 0·90 0·38, 2·14 0·812
40–49 years 20 29·4 112 25·6 0·73 0·37, 1·47 0·379
50–59 years 14 20·6 120 27·4 1·12 0·53, 2·37 0·765
60 years and above 17 25·0 130 29·4 Reference
Cigarette smoking
Yes 24 35·3 64 14·6 3·19 1·81, 5·60 <0·001
No 44 64·7 374 85·4 Reference
Alcohol consumption
Yes 32 47·1 134 30·6 2·01 1·20, 3·38 0·008
No 36 52·9 304 69·4 Reference
Stage of cancer
Unknown 4 6·0 23 5·4 1·09 0·34, 3·52 0·882
Stage 0 0 0 4 0·9 UD UD
Stage 1 12 17·9 63 14·8 0·99 0·45, 2·19 0·995
Stage 2 10 14·9 121 28·3 2·30 1·02, 5·17 0·044
Stage 3 22 32·8 116 27·2 1·00 0·51, 1·95 0·996
Stage 4 19 28·4 100 23·4 Reference
Site of cancer
Lip, oral cavity and pharynx (C00–14) 12 17·6 82 18·7 Reference
Digestive organs (C15–26) 30 44·1 80 18·3 2·56 1·22, 5·35 0·012
Respiratory organs (C30–39) 2 2·9 6 1·4 2·28 0·41, 12·6 0·346
Bone, cartilage, melanoma (C40–43) 4 5·9 142 32·4 1·95 0·55, 6·92 0·3
Breast (C50) 4 5·9 142 32·4 0·19 0·60, 0·62 0·006
Female genital (C51–58) 13 19·1 100 22·8 0·89 0·38, 2·05 0·782
Haematopoietic (C81–96) 2 2·9 7 1·6 1·95 0·36, 10·52 0·436
Kaposi sarcoma (C46) 1 1·5 7 1·6 0·97 0·11, 8·65 0·983
Type of treatment
Chemotherapy 36 61 323 80·8 Reference
Surgery 8 13·6 22 5·5 3·26 1·35, 7·86 0·008
Radiotherapy 14 23·7 53 13·3 2·37 1·19, 4·69 0·013
Hormonal therapy 1 1·7 2 0·5 4·49 0·39, 5·71 0·225
UD, undetermined; ESPEN, European Society of Clinical Nutrition and Metabolism.
* Based on ESPEN diagnostic criterion for malnutrition (BMI < 18·5 kg/m2).
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of the patients reported having poor appetite and feeling fati-
gued, while 35 % felt nauseated and 28 % reported vomiting.
Inadequate dietary diversity was associated with low BMI.
Previous studies have pointed out alterations that occur in
components of energy expenditure that can contribute to mal-
nutrition if not compensated for by increased energy intake(27).
Thus, a holistic approach is required to address the physical,
social, psychological and nutritional needs of cancer out-
patients to reduce the consequences of cancer-associated
nutritional decline(27,28).
BMI is the most common and easily available anthropomet-
ric assessment method despite its limitation. The local diag-
nostic criterion is BMI < 18 kg/m2, which is similar to the
ESPEN criteria. The low BMI criterion was able to identify
a higher proportion of patients with malnutrition compared
with the combined ﬁnding of unintentional weight loss and
either a reduced age-speciﬁc BMI or a low sex-speciﬁc
FFMI criteria also recommended by ESPEN. However, the
observed low FFMI of 43·1 % highlights the need to
incorporate body composition assessments in nutritional
assessments. Body composition is not routinely measured in
Kenyan public hospitals despite the morbidity risk associated
with increased loss of muscle mass. Given its relevance,
assessment of body composition should be supported by
building the necessary capacity and infrastructure(29–36). On
the other hand, the Fearon criteria for diagnosis of cachexia
identiﬁed 14·1 % cachexia compared with 8·5 % using the
local criteria. There is need therefore to evaluate the current
local diagnostic criteria for cachexia while being cognizant of
the local clinical practice and health system structures.
In this study, malnutrition and cachexia were signiﬁcantly
associated with treatment type and site of cancer. A previous
study in Kenya among cervical cancer patients undergoing
radiotherapy projected a 2-year survival of <20 %(37). Cancer
management therefore requires a multimodal approach, and
the Kenyan Government recommends establishment of
‘multidisciplinary tumour boards’ to consider all aspects of
the patients’ conditions(7). A multidisciplinary team is required
Table 4. Sociodemographic and clinical factors associated with cachexia
(Numbers and percentages; odds ratios and 95 % confidence intervals)
With cachexia* Without cachexia*
Characteristic n % n % OR 95 % CI P
Overall 72 14·1 440 85·9
Sex
Female 32 44·4 335 76·1 Reference
Male 40 55·6 105 23·9 3·99 2·39, 6·67 <0·001
Age
<30 years 10 13·9 12 2·7 6·52 2·45, 17·36 <0·001
30–39 years 9 12·5 63 14·3 1·12 0·47, 2·65 0·8
40–49 years 17 23·6 116 26·4 1·15 0·56, 2·35 0·708
50–59 years 19 26·4 116 26·4 1·28 0·63, 2·58 0·488
60 years and above 17 23·6 133 30·2 Reference
Cigarette smoking
Yes 28 38·9 61 13·9 3·95 2·29, 6·82 <0·001
No 44 61·1 379 86·1 Reference
Consuming alcohol
Yes 33 45·8 135 30·7 1·91 1·15, 3·17 0·012
No 39 54·2 305 69·3 Reference
Stage of cancer
Unknown 6 8·5 21 4·9 1·33 0·48, 3·71 0·581
Stage 0 0 0·0 4 0·9 UD 0·999
Stage 1 13 18·3 62 14·5 0·98 0·45, 2·09 0·955
Stage 2 9 12·7 125 29·1 0·34 0·15, 0·77 0·01
Stage 3 22 31·0 119 27·7 0·86 0·45, 1·66 0·659
Stage 4 21 29·6 98 22·8 Reference
Site of cancer
Lip, oral cavity and pharynx (C00–14) 17 23·6 77 17·5 Reference
Digestive organs (C15–26) 27 37·5 84 19·1 1·45 0·73, 2·88 0·28
Respiratory organs (C30–39) 2 2·8 7 1·6 1·29 0·24, 6·78 0·76
Bone, cartilage, melanoma (C40–43) 4 5·6 14 3·2 1·29 0·37, 4·42 0·681
Breast (C50) 6 8·3 141 32·0 0·19 0·07, 0·51 0·001
Female genital (C51–58) 13 18·1 103 23·4 0·57 0·26, 1·24 0·16
Haematopoietic (C81–96) 3 4·2 6 1·4 2·26 0·51, 9·97 0·28
Kaposi sarcoma (C46) 0 0·0 8 1·8 UD UD
Type of treatment
Chemotherapy 41 63·1 323 80·8 Reference
Surgery 6 9·2 24 6·0 1·97 0·76, 5·10 0·163
Radiotherapy 17 26·2 51 12·8 2·63 1·39, 4·97 0·003
Hormonal therapy 1 1·5 2 0·5 3·94 0·35, 44·40 0·267
UD, undetermined.
* Diagnosis based on Fearon criteria for assessment of cachexia (BMI < 20 kg/m2 and any degree of weight loss >2 %).
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to consider the implications beyond patients’ dietary needs to
patients’ nutritional and functional state throughout the pro-
longed course of treatment, and is best started earlier rather
than later(20,35,38). The role of nutrition as a therapy that com-
plements basic treatment and improves treatment outcomes
needs to be appreciated(22,38,39). Inclusion of nutritionists in
mainstream oncology practice has the potential to improve
early detection and screening of malnutrition, access to nutri-
tion services and communication for improved patient man-
agement(22,40). Awareness and consideration of nutritional
issues among oncologists and other related health disciplines
are also vital to the success of nutrition support in cancer
care(24,36). In settings with limited nutritionists/dietitians, pro-
vision of protocols for screening can enable task shifting that
has been shown to be effective and affordable in improving
access to healthcare(41).
Findings on sociodemographic and behavioural factors add
insights to the likely inﬂuence of social factors in the manage-
ment of cancer. Disease-aggravating factors such as cigarette
smoking and alcohol consumption were prevalent and signiﬁ-
cantly associated with the presence of malnutrition. Cigarette
smoking was a predictor of cachexia. Public sensitisation on
the ill-effects of such risk factors and raising the suspicion
index among healthcare workers is important. The Global
Burden of Disease 2016 report(23) showed that mortality due
to all cancers is largely located on the African continent and
expected to increase due to the epidemiological transition.
Continued research and surveillance therefore remain critical.
Further research is needed to understand the nutrition require-
ments in various care settings, and explore novel cancer pre-
ventive and control strategies(19,38). The emergence of
population-based cancer registries in East Africa should be
supported, and so should prioritisation of cancer control pro-
grammes within the health-care systems(19,42–44).
Conclusions
Malnutrition and cachexia remain a challenge among cancer
out-patients in Nairobi, Kenya, yet the provision of nutritional
services remains low. The use of the MUST as a screening tool
at the ﬁrst point of care has the potential to identify patients at
risk of malnutrition and who are likely to beneﬁt from appro-
priate interventions for better health outcomes. The local diag-
nostic criteria for cachexia should be reassessed to ensure
correct identiﬁcation of patients at risk of cachexia for initi-
ation of appropriate care. There is need for inclusion of
body composition assessments in Kenyan public hospitals
for reﬁned nutritional assessments that will in turn inform
patient management plans. Age is a common predictor of mal-
nutrition and cachexia in addition to site of cancer for malnu-
trition and cigarette smoking for cachexia. Tailored education
and sensitisation campaigns should therefore be encouraged
and multidisciplinary partnerships formed to provide holistic
cancer care.
Limitations
The study did not measure inﬂammatory markers or ascertain
the aetiology of malnutrition observed. The contribution of
inﬂammation and other catabolic drivers to the development
and progression of cachexia was also not assessed. This was
partly due to the design of the study and the choice of out-
patients in whom tests for inﬂammatory markers are not rou-
tinely done in the selected study facilities.
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